ALS Clinical Trials: New Hope After Phase 3 Setbacks
“Some may look at recent failures and be discouraged,” wrote Richard Bedlack of the Duke ALS Clinic in Durham, North Carolina, in an e-mail to Alzforum. Thanks to advances in genetics and biomarkers, and a list of potential target pathways, “I think this is a time of unprecedented hope and excitement in ALS research”
Categories: Clinical Trials, Research News, Treatments
| 
Tags: ALS, ALS clinical trials, ALS community, ALS Functional Rating Scale (ALSFRS), ALS Phase 3 studies, ALS research, ALS research funding, ALS sodium chlorite, ALS TDI, ALS Therapy Development Institute, ALS treatments, amyotrophic lateral sclerosis, Angela Genge, Annual Symposium on Amyotrophic Lateral Sclerosis/Motor Neuron Disease, antisense oligonucleotide therapy ALS, astrocyte excitatory amino acid transporter 2, Benjamin Brooks, Biogen Idec, biomarkers ALS, Bob Stehlin, ceftriaxone, CK-2017357, cytochrome P450 1A2, Cytokinetics, dexpramipexole, Dr. Timothy Miller, Duke ALS Clinic Durham, Emory University Atlanta, Evan Snyder, FDA, fingolimod, Food and Drug Administration, Forbes Norris MDA/ALS Research Center, genetics ALS, Gilenya, immune-system drugs ALS, Inc., ISIS 333611, Isis Pharmaceuticals, Jeremy Shefner, Jonathan Glass, Les Turner ALS Foundation, Lou Gehrig's disease, Massachusetts General Hospital, Merit Cudkowicz, mitochondrial modulator, Montréal Neurological Institute and Hospital, mutant human superoxide dismutase 1, mutant superoxide dismutase 1, Neil Cashman, Neuralstem Inc, Neuraltus, North Carolina, Northeast ALS Consortium, Novartis, NP001, olesoxime, oligonucleotide, oligonucleotide ALS, oligonucleotide via intrathecal infusion, PALS, Phase III trial ALS, Pitié-Salpêtrière Hospital, RASCALS Foundation, Richard Bedlack, riluzole, Robert A. Stehlin Campaign for ALS, Robert Brown, Robert Miller, Sanford-Burnham Medical Research Institute, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, State University of New York Upstate Medical University, stem cell trial ALS, Steven Perrin, Susanna Benn, synaptic glutamate, target pathways ALS, Tim Miller, Timothée Lenglet, Tirasemtiv, troponin ALS, University of British Columbia, University of Massachusetts Medical School Worcester, University of North Carolina School of Medicine, Washington University St. Louis, Wendy Abrams, Yang Teng, Yang Teng of Brigham and Women’s Hospital
| 
No comments